Company news

Tango Therapeutics, Inc. news in 2026

Tango Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

November 4, 2026

Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference

November 3, 2026

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

October 23, 2026

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

October 16, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 11, 2026

Tango Therapeutics Announces Executive Chair Transition

August 6, 2026

Tango Therapeutics Appoints Robert Azelby to Board of Directors

June 22, 2026

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

June 9, 2026

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

June 8, 2026

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 13, 2026

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

April 14, 2026

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

March 5, 2026

Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

March 4, 2026

Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

February 17, 2026

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 2, 2026

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

January 8, 2026

Tango Therapeutics Appoints Sung Lee to Board of Directors

January 4, 2026

Decks in 2026